Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Total Operating Expenses?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Total Operating Expenses is 
$2.9B (1Y +11.9% )

ALXN Stock Price & Total Operating Expenses

Total Operating Expenses for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Total Operating Expenses

chevron_right 2021 $792.6M +395x
( +24.8% / year avg)
chevron_left 1995 $2.0M
vertical_align_top Peak $2.6B +1293x
vertical_align_bottom Bottom $2.0M
arrow_drop_up # Up Years 24 24 of 27
years up.
arrow_drop_down # Down Years 3
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.11x the rate relative to it's total operating expenses over the same period.
  • If ALXN grows it's stock at the same rate as it's total operating expenses (+24.8%/year) , it's stock price will grow +916% and hit $996.45 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 24 years (0%) it's total operating expenses were also up.
  • ALXN Historical Total Operating Expenses Table
    in $ million
    Year Total Operating Expenses YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $792 -69.4% - -
    4/1/2020 $2,588 10.8% - -
    4/1/2019 $2,336 6.2% - -
    4/1/2018 $2,199 0.2% - -
    4/1/2017 $2,196 47.1% - -
    4/1/2016 $1,492 0.3% - -
    4/1/2015 $1,488 41.6% - -
    4/1/2014 $1,051 37.9% - -
    4/1/2013 $762 38.0% - -
    4/1/2012 $552 33.0% - -
    4/1/2011 $415 34.0% - -
    4/1/2010 $310 32.8% - -
    4/1/2009 $233 25.4% - -
    4/1/2008 $186 15.0% - -
    4/1/2007 $161 33.0% - -
    4/1/2006 $121 -3.2% - -
    4/1/2005 $125 61.4% - -
    4/1/2004 $77 -4.8% - -
    4/1/2003 $81 4.1% - -
    4/1/2002 $78 65.4% - -
    4/1/2001 $47 5.0% - -
    4/1/2000 $45 32.7% - -
    4/1/1999 $34 105.4% - -
    4/1/1998 $16 37.2% - -
    4/1/1997 $12 21.0% - -
    4/1/1996 $10 400.0% - -
    4/1/1995 $2 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Total Operating Expenses is a company's earnings from its normal operations before any non-operating income and/or costs such as interest expense, taxes, and special items. Income at the operating level, which is viewed as more reliable, is often used by financial analysts rather than net income as a measure of profitability.

    For more detailed definitions, please see Investopedia.